

## **Aerosol Generating Procedures**

Dear customers and colleagues

In the context of the COVID-19 pandemic, Cyclomedica has been asked if the administration of Technegas<sup>™</sup> in clinical settings is an aerosol generating procedure (AGP). It is Cyclomedica's position that the administration of Technegas<sup>™</sup> is not an AGP.

It is widely accepted around the world that AGPs stimulate coughing and promote the generation of aerosols <u>from a patient's lungs</u>.

According to the UK's National Health Service, the following procedures are considered to be potentially infectious AGPs: Intubation, extubation and related procedures; Tracheotomy/tracheostomy procedures; manual ventilation; open suctioning; Bronchoscopy; Non-invasive ventilation (NIV) e.g. Bi-level Positive Airway Pressure (BiPAP) and Continuous Positive Airway Pressure ventilation (CPAP); Surgery and post-mortem procedures in which high-speed devices are used; High-frequency oscillating ventilation (HFOV); High-flow Nasal Oxygen (HFNO); Induction of sputum; and some dental procedures (e.g. high speed drilling).

Technegas is an ultrafine suspension of technetium radiolabelled carbon particles in argon. During a Technegas<sup>™</sup> administration procedure, the patient is required to undertake normal breathing through the mouthpiece of a patient administration set (PAS). Technegas<sup>™</sup> is not known to be a respiratory irritant stimulating patients to cough or promote the generation of aerosols. To reiterate, it is Cyclomedica's position that the <u>administration of Technegas<sup>™</sup> is not an AGP</u>.

The Centers for Disease Control and Prevention in the United States recommends that health care staff wear gowns, gloves and eye protection (goggles or face shields, not personal eyeglasses) when caring for patients with suspected or confirmed cases of COVID-19. Cyclomedica endorses such prudent advice.

If you require additional information, please do not hesitate to contact Cyclomedica via email at info@cyclomedica.com.au

**Dr Mark Doverty** 

Global Head of Regulatory Compliance

& Clinical Research

**20** March 2020